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Heterologous protection against malaria by a
simple chemoattenuated PfSPZ vaccine regimen in
a randomized trial
Zita Sulyok1,2,7, Rolf Fendel 1,2,7✉, Bianca Eder1,2, Freia-Raphaella Lorenz 1,2, Natasha KC3,
Matthias Karnahl1,2, Albert Lalremruata 1,2, The T. Nguyen1,2, Jana Held1,2,
Folashade Almeine Cyntiche Adjadi1,2, Torsten Klockenbring4, Judith Flügge1,2, Tamirat Gebru Woldearegai1,2,
Carlos Lamsfus Calle 1,2, Javier Ibáñez 1,2, Miriam Rodi1,2, Diane Egger-Adam1,2, Andrea Kreidenweiss 1,2,
Carsten Köhler1,2, Meral Esen1,2, Mihály Sulyok1,2, Anita Manoj3, Thomas L. Richie3, B. Kim Lee Sim3,
Stephen L. Hoffman3,7, Benjamin Mordmüller 1,2,5,7 & Peter G. Kremsner1,2,6,7
Immunization with Plasmodium falciparum (Pf) sporozoites under chemoprophylaxis (PfSPZ-
CVac) is the most efficacious approach to malaria vaccination. Implementation is hampered
by a complex chemoprophylaxis regimen and missing evidence for efficacy against hetero-
logous infection. We report the results of a double-blinded, randomized, placebo-controlled
trial of a simplified, condensed immunization regimen in malaria-naive volunteers (EudraCT-
Nr: 2018-004523-36). Participants are immunized by direct venous inoculation of 1.1 × 105
aseptic, purified, cryopreserved PfSPZ (PfSPZ Challenge) of the PfNF54 strain or normal
saline (placebo) on days 1, 6 and 29, with simultaneous oral administration of 10 mg/kg
chloroquine base. Primary endpoints are vaccine efficacy tested by controlled human malaria
infection (CHMI) using the highly divergent, heterologous strain Pf7G8 and safety. Twelve
weeks following immunization, 10/13 participants in the vaccine group are sterilely protected
against heterologous CHMI, while (5/5) participants receiving placebo develop parasitemia
(risk difference: 77%, p= 0.004, Boschloo’s test). Immunization is well tolerated with self-
limiting grade 1–2 headaches, pyrexia and fatigue that diminish with each vaccination.
Immunization induces 18-fold higher anti-Pf circumsporozoite protein (PfCSP) antibody levels
in protected than in unprotected vaccinees (p= 0.028). In addition anti-PfMSP2 antibodies
are strongly protection-associated by protein microarray assessment. This PfSPZ-CVac
regimen is highly efficacious, simple, safe, well tolerated and highly immunogenic.
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The global disease burden of malaria is a major public healthchallenge. The World Health Organization (WHO) esti-mated a total of 228 million cases and 405,000 deaths in
2018 worldwide; the majority caused by Plasmodium falciparum
(Pf) in sub-Saharan Africa1. Despite the decreasing incidence in
many countries, the economic and social consequences of malaria
are still enormous. New interventions for prevention and treat-
ment are critically needed to control and eradicate the disease. An
effective vaccine would be an ideal additional tool to reach this
goal. However, developing a vaccine against parasites is particu-
larly challenging because of their complexity in genome size, life
cycle, epidemiology, and immunology. The only vaccine against
malaria that has completed clinical development is RTS,S, a
recombinant protein vaccine targeting the Pf circumsporozoite
protein (PfCSP), the predominant sporozoite surface protein. It
received a positive scientific opinion from the European Medi-
cines Agency in 2015 but has not received marketing approval
(licensure) so far due to moderate vaccine efficacy (VE) and
inconclusive safety signals2,3.
Whole-cell Pf sporozoite (PfSPZ)-based vaccines are a pro-
mising way to evoke immunity, since a broad antigenic repertoire
of the parasite is present in the pre-erythrocytic development
stages, especially in the liver phase.
The history of attempts in humans to develop such a vaccine
dates back to the 1970s4,5. The translation of experimental immu-
nization using mosquito bites into a candidate vaccine was only
recently achieved by developing aseptic, purified, cryopreserved
PfSPZ for use in humans6. Availability of PfSPZ products boosted
the development of malaria vaccines. It was shown in previous trials
that immunization with whole-cell sporozoites, either radiation-
attenuated (PfSPZ Vaccine)7–11 or chemoattenuated by the con-
comitant administration of an antimalarial (PfSPZ chemoprophy-
laxis vaccine, PfSPZ-CVac)12–14, is highly immunogenic and
induces robust protection against homologous (vaccine) strain-
controlled human malaria infection (CHMI). However, after mos-
quito bite immunization with this approach, which is called che-
moprophylaxis with sporozoites (CPS), VE against heterologous
(non-vaccine) strain CHMI was minimal15,16.
In our previous PfSPZ-CVac trial TÜCHMI-002 (NCT02115516),
we showed that direct venous inoculation (DVI) administration of
three doses of 5.12 × 104 PfSPZ Challenge (infectious PfSPZ) over
8 weeks under weekly chloroquine (CQ) chemoprophylaxis protected
100% (9/9) of study participants against CHMI conducted with the
homologous (vaccine) strain of Pf and performed 10 weeks after
immunization12. CQ, a blood schizonticide without effect on liver
stages, was selected as the partner drug rather than a liver active drug
to allow parasite multiplication within hepatocytes, thereby increas-
ing the antigenic stimulus and the expression of late liver stage and
early blood stage antigens. However, this regimen was suboptimal for
a routine setting as it required 13 clinic visits including ten for
administration of CQ. In the second cohort of this trial, a condensed
immunization regimen requiring fewer doses of CQ was selected.
Here, three doses of 5.12 × 104 PfSPZ Challenge at 5- or 14-day
intervals protected 63% (5/8) and 67% (6/9) of volunteers,
respectively12. These results indicated that shorter regimens with
fewer doses of CQ could be used, although potentially at the cost of
reduced VE.
Building on these data, the aim of the current study was to
establish a condensed immunization regimen of three injections
of PfSPZ Challenge offering improved VE compared to the prior
condensed regimens. To compensate for the potentially reduced
VE due to the condensed regimen and heterologous CHMI, the
dose was increased from the previously administered dose (5.12 ×
104 PfSPZ Challenge)12 to a dose of 1.1 × 105 PfSPZ Challenge
per injection. To facilitate the procedure for future application
(e.g. in endemic countries and for travelers) CQ was given only
on the days of PfSPZ Challenge injection, thereby requiring only
three visits to complete vaccination (Fig. 1). Additionally, we
aimed to determine if a condensed regimen with increased dose
of PfSPZ Challenge protected against heterologous CHMI.
Results
Description of study population. We enrolled 21 volunteers
from 30 April 2019 to 15 May 2019. One participant dropped out
due to a new onset ECG abnormality on Day 1 before any study
treatment was given. Hence, 20 volunteers were randomized and
received at least one immunization (intention to treat popula-
tion). A total of 18 participants underwent all three immuniza-
tions and CHMI (per protocol population). Two volunteers
withdrew consent after the second immunization and received
rescue treatment with atovaquone/proguanil on Days 34, 35, and
a
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Fig. 1 Diagram illustrating the differences between the established and current vaccination regimen for PfSPZ-CVac (CQ). a The previously used
vaccination regimen included 13 clinic visits during 9 weeks, 10 for administration of CQ, and 3 for immunizations12. b The immunization regimen assessed
in this study included three clinic visits during 4 weeks, three for administration of CQ, and the same three for immunizations. Red arrows: vaccination time
points; blue arrows: chloroquine treatment time points.
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36 (later identified as placebo recipients). Third immunization
was postponed in the case of one volunteer (to Day 35 instead of
Day 28) because of an acute gastroenteritis (later identified as
placebo recipient). Baseline characteristics and study flow chart
are shown in Table 1 and Fig. 2.
Parasitemia during immunization. We had previously shown
that transient parasitemia develops 7 days after administration of
5.12 × 104 PfSPZ Challenge (PfNF54) during immunization and
the peak parasite density diminishes after each of three
immunizations12. In this study, after administration of 1.1 × 105
PfSPZ Challenge (PfNF54) parasite density peaked 8 days after
each immunization, but never reached the levels seen with half
the dose of immunizing PfSPZ in our first study (median peak
parasite density after first dose was 15,755 vs 1012 parasites/ml in
this study) (Fig. 3). In the previous study 7/9 (78%) subjects had
detectable parasitemia after the third immunization12, but in this
study only 7 of the 13 vaccinees (54%) had any detectable para-
sitemia (Fig. 3).
Vaccine efficacy. After CHMI with heterologous PfSPZ (7G8),
10/13 vaccine and 0/5 placebo volunteers were sterilely protected.
VE compared to placebo was 77% (95% CI: 13–95%, p= 0.004,
Boschloo’s test, two tailed). Participants developed parasitemia
detected by quantitative real-time reverse transcriptase PCR (RT-
qPCR) with a median prepatent period of 7 days (interquartile
range (IQR) 0) after CHMI; median peak parasite density was
2925 parasites/ml (IQR 2168–6218) in the three unprotected
vaccine participants and 11,555 parasites/ml (IQR 7937–12,563)
in the placebo group. Median time to treatment threshold was
9 days (IQR 9.0–10.0) in the placebo group and 10 days (IQR
9.5–12.0) in the unprotected vaccinated participants, which was
Table 1 Demographic data.
Number of participants (n= 20) Vaccine Placebo P value
Sex
Male (n, percentage) 6 (46%) 5 (71%) p= 0.37*
Female (n, percentage) 7 (54%) 2 (29%)
Age in years (median, range) 25 (19–42) 26 (21–36) p= 0.79**
Height in cm (median, range) 171 (159–184) 178 (165–188) p= 0.14**
Weight in kg (median, range) 69 (50–100) 73 (51–86) p= 0.92**
BMI in kg/m2 (median, range) 23.8 (16.9–33.8) 23.2 (18.7–25.6) p= 0.50**
*Two-sided Fisher’s exact test.
**Two-sided Student’s t-test.
Assessed for eligibility (n=35)
Excluded (n=15)
 Not meeting inclusion criteria 
(n=13)
 Declined to participate (n=1)






Allocated to vaccine (n=13)
 Received allocated intervention 
(n=13)
Analysed (n=13)
 Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to placebo (n=7)
 Received allocated intervention 
(n=7)
Lost to follow-up (n=0)
Discontinued intervention (consent 
withdrawn) (n=2)
Analysed (n=5)
 Excluded from analysis (n=0)
Fig. 2 Study flow chart. CONSORT flow diagram showing study participant flow through for each individual stage of the randomized controlled vaccination
trial (enrollment, allocation, follow-up, and analysis).
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not significantly different (Fig. 4). Distribution of age between the
two groups was similar (median age of 29 years in unprotected vs
26 years in protected vaccinees, Mann–Whitney test, p= 0.84).
Of note, all unprotected participants were males.
The 10 protected individuals in general had higher levels of
parasitemia after the first two doses of PfSPZ-CVac (Fig. 3), but
after the third dose, one unprotected subject had a high
parasitemia above 1000 parasites/ml. Only 6 of the 10 protected
subjects and 1 of the 3 unprotected subjects had a parasitemia
level above the detection limit after the third immunizing dose;
the other six of these subjects did not develop any detectable
parasitemia (detection limit: 6 parasites/ml) after injection with a
dose of PfSPZ Challenge (PfNF54) that was 34.5 times higher
than the 100% infectious dose of PfSPZ Challenge (PfNF54) used
for CHMI.
Safety and reactogenicity. There were no related grade 3 adverse
events (AEs) or serious adverse events (SAEs) during the
immunization phase, but there was one unrelated grade 3 AE, a
case of diastolic hypertension. In all, 222 grade 1 or 2 AEs
occurred during the immunization period. One hundred and
thirty-five (109 in vaccinees and 26 in controls) were considered
as possibly, probably, or definitely related to the investigational
product (Table 1). Headache and/or dizziness occurred in 92.3%
of vaccinees and 71.4% of controls, and fatigue in 69.2% of
vaccinees and 42.9% of the controls, suggesting that CQ may have
played a significant role in causing AEs. Solicited grade 1 and 2
AEs within the first 5 days following the first and third immu-
nization are summarized in Table 2. Nervous system disorders
occurred in 46% of vaccinees and 43% of placebo controls after
the first vaccination/CQ treatment, and 46% and 14% after third
vaccination/CQ treatment for vaccinees and placebo controls,
respectively (Supplementary Table 2). The second vaccine
administration is not shown as this time overlaps with the time
period of transient parasitemia. At most, three AEs occurred per
individual per day, and they primarily occurred shortly after CQ
treatment or during transient parasitemia on days 7 or 8 (Fig. 5).
The range of AEs occurring in subjects in the vaccinated and
placebo groups was 1–17 AEs and 1–7 AEs, respectively (Fig. 6).
There was no significant difference between the 13 vaccinees
and 7 controls in regard to any single AE at the time of peak
parasitemia (Fig. 3a) after each of the three immunizations, which
was on days 7–9 after each dose (Fig. 3b). However, after each
dose, there was a higher frequency of headache in vaccinees (62,
15, and 31%) as compared to controls (14, 14, and 14%); the
difference in the frequency after the first dose was 62% vs 14%
(p= 0.07, Fisher’s exact test, two sided). No other AE occurred
during this time window after any dose in more than 32% of
vaccinees or controls. The highest incidence of pyrexia occurred
after the first dose (23% vs 0%, p= 0.25); 15% vs 0% after second
dose, and 8% vs 0% after the third dose. The participant with
pyrexia after the third dose had the highest parasitemia on day 8
after vaccination (1262 parasites/ml). All of these AEs were grade
1 or 2 (Supplementary Table 2).
Six of the eight participants, who developed parasitemia during
CHMI, experienced at least one AE related to malaria, including
one grade 3 AE (neutropenia). Volunteers were treated with
atovaquone/proguanil according to the national guidelines and all
recovered uneventfully.
One unrelated SAE occurred in the late follow-up period. On
day 63 after CHMI, one vaccinee underwent an elective surgery


























Group Vaccine dose Dose 1 (day 1) Dose 2 (day 6) Dose 3 (day 29)
All vaccinated 1.1 x 105 PFSPZ 13/13; 1012; 9 13/13; 491; 14 7/13; 33; 37
Protected 1.1 x 105 PFSPZ 10/10; 1187; 9 10/10; 651; 14 6/10; 25; 37
Unprotected 1.1 x 105 PFSPZ 3/3; 501; 9 3/3; 150; 13 1/3; 1262; 37
b
Fig. 3 Parasitemia during immunization phase. a Parasitemia (parasites/
ml) was estimated by quantitative PCR during the immunization phase after
immunizations 1, 2, and 3. Individual parasitemia levels are shown. Red
circles: vaccinated group (protected); turquoise triangles: vaccinated group
(unprotected). During the first vaccination period, one unprotected vaccinee
missed visits of Study days 9 and 10 after immunization, two volunteers
missed the visit on Study day 10 after immunization. At second
immunization, one protected volunteer missed the visit on Study day 15. For
the third immunization, one unprotected and one protected vaccinee missed
the visit on Study day 38 after immunization. b Number of subjects positive
per number injected, median peak parasite density among positives, and
study day of median peak parasite density among positives after each dose
of PfSPZ-CVac. Values are given for all vaccinated volunteers as well as
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Fig. 4 Kaplan–Meier plot of time from infection to treatment initiation.
The overall time to treatment (in days) after injection of 3.2 × 103 PfSPZ
Challenge (onset of CHMI) is presented for both the placebo (n= 5) and
the vaccinated (n= 13) groups. The cross represents the censoring event at
the end of the follow-up period of the specific CHMI (day 28 after CHMI).
Two volunteers receiving placebo withdrew consent before CHMI; these
individuals were not included in the survival analysis. Time to treatment:
treatment was initiated at time of parasitemia. Parasitemia as the CHMI
endpoint was defined as at least one qPCR result above 100 parasites/ml
among three positive results at least 12 h apart or as a positive thick
blood smear.
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Immunogenicity against PfCSP. IgG antibody responses (net
OD 1.0) to PfCSP 2 weeks after the third dose and just prior to
CHMI were 17.6 and 18.1 times higher in uninfected (protected)
(N= 10) vs infected (N= 3) vaccinees (p= 0.028 and 0.049)
(Fig. 7a). Quantification by a second assay of anti-PfCSP-specific
IgG one day before CHMI showed that median PfCSP-specific
IgG was 10-fold higher in protected (127 µg/ml, 95% confidence
interval (CI): 36–231 µg/ml) than in unprotected vaccinees
(18 µg/ml, 95% CI: 6–33 µg/ml). Median levels of IgM antibodies
to PfCSP 2 weeks after the third dose and 1 day before challenge
were 6.7 and 2.5 higher in uninfected (protected) vs infected
vaccinees, but differences did not reach the level of statistical
significance (p= 0.112 and 0.119) (Supplementary Fig. 1). IgG
antibody responses to PfCSP were in general highest 2 weeks after
the third dose and remained elevated through 28 days after
CHMI (Supplementary Fig. 2A). IgM response also peaked after
Table 2 Related grade 1 and 2 AEs using MedDRA terminology during the immunization phase Days −2 to +42).
System organ class Preferred term Vaccine (N= 13) Placebo (N= 7)
Blood and lymphatic system disorders Lymphopenia [1] 1 (7.7%) –
#Total [1] 1 (7.7%) –
Cardiac disorders Tachycardia [2] 2 (15.4%) –
#Total [2] 2 (15.4%) –
Gastrointestinal and abdominal pains (excl. oral and throat) Abdominal pain [1] 1 (7.7%) [2] 1 (14.3%)
#Total [1] 1 (7.7%) [2] 1 (14.3%)
Gastrointestinal disorders Diarrhea [2] 2 (15.4%) [1] 1 (14.3%)
Nausea [7] 6 (46.2%) [3] 2 (28.6%)
#Total [9] 7 (53.8%) [4] 3 (42.9%)
General disorders and administration site conditions Chills [3] 3 (23.1%) [1] 1 (14.3%)
Fatigue [16] 9 (69.2%) [3] 3 (42.9%)
Hyperhidrosis [4] 4 (30·8%) –
Malaise [4] 3 (23.1%) –
Pyrexia [8] 5 (38.5%) [1] 1 (14.3%)
#Total [35] 10 (76.9%) [5] 3 (42.9%)
Infections and infestations Oral herpes – [1] 1 (14.3%)
#Total – [1] 1 (14.3%)
Musculoskeletal and connective tissue disorders Back pain [1] 1 (7.7%) –
Myalgia [5] 4 (30.8%) [1] 1 (14.3%)
#Total [6] 4 (30.8%) [1] 1 (14.3%)
Nervous system disorders Dizziness [15] 7 (53.8%) [4] 2 (28.6%)
Headache [35] 12 (92.3%) [8] 4 (57.1%)
Paresthesia [1] 1 (7.7%) –
Vision blurred [3] 2 (15.4%) –
#Total [54] 12 (92.3%) [12] 5 (71.4%)
Psychiatric disorders Depersonalization/derealization disorder – [1] 1 (14.3%)
#Total – [1] 1 (14.3%)
Respiratory, thoracic, and mediastinal disorders Tachypnoea [1] 1 (7.7%) –
#Total [1] 1 (7.7%) –
In square brackets: number of events; number of patients with events; in brackets: percentage of patients with event.
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Fig. 5 Adverse events (AEs) over time during immunization period. AEs
during the immunization period were recorded for each individual. The total
number of mild and moderate AEs per individual (rows) and per day
(columns) are plotted as a heatmap. The study population was divided into
the subgroups of treatment allocation and CHMI outcome. Numbers of AEs
are represented as given by the color scheme in the legend. Arrows
highlight the time points of injection of the investigational product. Bars in
burgundy indicate the period of transient parasitemia in vaccinees. AEs on
Day 1 occurred after administration of investigational product. There were
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Fig. 6 The number of adverse events (AEs) during the immunization
period in the placebo and vaccine groups. Each bar represents one
volunteer sorted on the number of AEs from the time of first injection with
normal saline or PfSPZ Challenge until the end of the vaccination period.
Mild (grade 1) AEs are depicted in red, moderate (grade 2) in turquoise.
Non-protected volunteers are marked with an “M” on the x-axis.
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PfMSP2   PF3D7_0206800
PfARP_seg1   PF3D7_0108300
PfMSA180_seg1a   PF3D7_1014100
PfApiAP2   PF3D7_1139300
PfLISP2_seg2   PF3D7_0405300
PfLSA1_seg3   PF3D7_1036400
PfLSA1_seg1b   PF3D7_1036400
PfCSP   PF3D7_0304600
0.2 0 0.2 0.4 0.6 0.8




Fig. 7 IgG antibody reactivity against Plasmodium falciparum antigens. a IgG antibody levels specific for PfCSP were measured by ELISA using sera from
volunteers before the first immunization (D-1), 15 days after the last immunization (D 44), as well as 1 day before CHMI (C-1). PfCSP-specific antibody
levels of baseline-corrected post-immunization time points (net OD 1.0) are shown. Green triangles: vaccinated group (protected); red squares: vaccinated
group (unprotected); blue circles: placebo controls. Reported data were derived from a single assessment with three technical replicates. N= 18
biologically independent study participants. Lines shown are median with 95% CI. P values were estimated by two-sided Wilcoxon–Mann–Whitney test.
b–d Sera from all volunteers collected before immunization (baseline, D-1) and one day before CHMI (C-1) were assessed on protein microarrays
containing 262 P. falciparum proteins representing 228 unique antigens. Analysis was performed on C-1 data after subtraction of the individual baseline
reactivity. b To estimate PfSPZ-CVac immunogenicity, antigen reactivity in vaccinated donors (to the right) was compared to the placebo controls (to the
left). Differentially recognized antigens (p value <0.05 and fold change >2) are depicted in red. P values were estimated using the two-sided Welch-
corrected Student’s t-test. c The fraction of seropositive vaccinated and placebo samples (seropositivity defined as at least fourfold overall baseline
reactivity) of the 25 most immunogenic antigens were assessed. d Individual antibody reactivities to the five most immunogenic proteins representing
sporozoite, liver, and early blood stage are presented stratified by the group allocation (placebo, unprotected, and protected vaccinees). The boxplot gives
median signal intensities, interquartile ranges (IQR), and whiskers of the length of 1.5 × IQR. N= 18 biologically independent study participants.
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the third dose, but decreased by the time of CHMI in most
volunteers (Supplementary Fig. 2B); thus, antibody levels were
not boosted during CHMI.
Immunogenicity estimated by protein microarrays. The overall
antibody response against the parasite in vaccinees compared to
the placebo controls was estimated by protein microarray17–20.
Before CHMI, significantly elevated antibody levels were detected
for multiple proteins (Fig. 7b). For the proteins PfLSA1 (Pf liver
stage antigen 1), PfMSA180, PfCSP, PfLISP2 (liver-specific pro-
tein 2), and Pf merozoite surface protein 2 (PfMSP2), more than
half of the vaccinated cohort reached antibody levels at least four
times higher than did placebo controls (Fig. 7c), corresponding to
a high effect size (Hedge’s g > 0.9).
Protection from development of blood stage parasitemia
following CHMI was associated with significant increases in five
Pf-specific antibodies, PfMSP2, sporozoite invasion-associated
protein 2 (PfSIAP2), chaperone protein DnaJ (PfDnaJ protein),
gametocytogenesis-implicated protein (PfGIG), and a member of
the erythrocyte membrane protein 1, PfEMP1 (p < 0.05, Welch’s
corrected Student’s t-test). As expected from the enzyme-linked
immunosorbent assay (ELISA) data, IgG levels against PfCSP
were higher in the protected than the unprotected vaccinees
(Hedge’s g > 0.8). Interestingly, antibodies against PfMSP2 were
7.5-fold increased in protected vs unprotected vaccinees (Supple-
mentary Fig. 3).
In order to verify the general vaccination effect in the
unprotected study population, the antibody levels against
representative markers of the different stages, which the parasite
pass through under CQ treatment, were more closely investigated
(Fig. 7d). Despite the lower PfCSP-specific reactivity of the
unprotected subjects in the vaccine group compared to the
protected subjects in the vaccine group, antibody levels against
early-to-mid liver stage antigens (PfLSA1, PfLISP2) and one late
liver stage antigen (PfMSA180) were similarly elevated in the
protected and the unprotected volunteers of the vaccine group.
IgG levels against PfMSP2 were as low in the vaccinated but
unprotected subjects as in the placebo group.
Concerning IgM antibody levels, PfMSP2, PfLSA1, and
PfMSA180 IgM antibodies were elevated in the vaccinees compared
to the placebo controls and only an asparagine-rich protein with
unknown function (conserved protein, PF3D7_0817300) was
associated with protection (Supplementary Fig. 4).
Discussion
Immunization with chemoattenuated PfSPZ in a condensed
regimen with three doses of 1.1 × 105 PfSPZ administered on
Days 1, 6, and 29 with 10 mg/kg CQ base protected 77% of
malaria-naive volunteers against heterologous CHMI 12 weeks
after the immunization. This study established three key princi-
ples that are critical for moving forward with PfSPZ-CVac: (1) VE
was demonstrated against a heterologous strain of Pf parasite, (2)
VE was achieved after a 4-week immunization period, and (3) VE
and safety were achieved while administering CQ only on the
days of administration of PfSPZ.
For implementation of this vaccine for use in endemic areas,
it was crucial to demonstrate VE against heterologous CHMI. It
has been reported that immunization by mosquito bite gave
only minimal protection against heterologous CHMI15,16. Here,
we used Pf7G8, which originates from Brazil. Compared to
PfNF54, Pf7G8 possesses tens of thousands of genetic varia-
tions, including regulatory and immunologically important
regions21. More importantly, Pf7G8 varies more from PfNF54
at the genome, proteome, and CD8 T cell immunome level than
do >700 Pf strains from East, West, and Central Africa21.
Furthermore, it has been shown that when the same immuni-
zation regimen of PfSPZ Vaccine is administered, it is more
difficult to protect against heterologous CHMI with Pf7G8 than
against field acquired malaria in Mali9,10. We think that we
achieved such good VE against a heterologous parasite, because
we increased the immunizing dose more than twofold from our
studies that gave 100% VE against homologous CHMI12, and
because immunization on Days 1 and 6 achieves multi-dose
priming, which enhances VE. In the mosquito bite CPS studies
that did not show heterologous VE15,16, the subjects were
immunized with only a maximum of bites from 15 infected
mosquitoes three times (total of 45). It requires the bites of five
Pf-infected mosquitoes or 3.2 × 103 PfSPZ of PfSPZ Challenge
to achieve 100% infection of subjects in CHMI5,22. The two
systems to infect humans with Pf sporozoites are difficult to
compare directly, as the number of Pf sporozoites injected by a
mosquito is highly variable, but nevertheless we estimate that
the dose of 15 mosquito bites is the equivalent of 9.6 × 103
PfSPZ, which is approximately a 10-fold lower dose than the
1.1 × 105 PfSPZ we used in this study.
A number of CPS and PfSPZ-CVac regimens with different
routes of administration (mosquito bite, intradermal injection,
DVI), intervals between doses and numbers of doses of PfSPZ
have been assessed in the last decade with intention to evoke
sterile VE. With PfSPZ administered by mosquito bite (CPS) or
by DVI (PfSPZ-CVac), VE was 75–100%12,13,23 against homo-
logous CHMI using longer vaccination schedules (three doses at
4-week intervals). Our results from a former PfSPZ-CVac trial
suggested that shorter three-dose regimens—desirable for general
use—show reduced VE. Therefore, in retesting a 5-day interval
between the first and second doses in this trial, we increased the
dose of PfSPZ and delayed the third dose from Day 11 to Day 29
to improve VE. The increased dose of PfSPZ might raise concerns
about a higher parasite density at the time of parasite egress from
the liver with more pronounced symptoms and signs of malaria,
eventually carrying a higher risk of a possible breakthrough
infection during the immunization phase. However, our data
showed that parasitemia was at submicroscopic levels and was
efficaciously cleared by the simplified dosing of CQ during
immunization. However, as in the previous study, parasite egress
into the blood 7–9 days after the first immunization was asso-
ciated with a non-significant, self-limiting increase in grade 1 or 2
headaches (62% of vaccinees), pyrexia (32%), and fatigue (31%);
the incidence rate was lower after second and third doses (Sup-
plementary Table 1).
In previous studies we administered a loading dose of 10 mg/kg
CQ base 2 days before the first immunization and then 5 mg/kg
weekly thereafter through 5 days after the last immunization for a
total of 10 doses (Fig. 1). This is a rigorous schedule to follow and
we have been concerned that if after administration of the first
dose of PfSPZ, vaccinees were lost to follow-up and did not take
their subsequent CQ doses, they could develop malaria. In this
study the CQ was administered prior to each dose, ensuring the
CQ was swallowed and retained before PfSPZ were administered
(Fig. 1). For all three doses 10 mg/kg CQ base was administered.
This approach was adequate to kill all the blood stage parasites.
However, 71.4% of the controls had headache and/or dizziness,
which we speculate to be attributed to CQ.
It would be useful if it was possible to predict protective effi-
cacy. One possibility might be the prediction of protection based
on the peak parasitemias seen after each immunizing dose. After
the first and second doses, vaccinees who were protected had
greater median levels of peak parasitemia (1187 vs 501 after first
dose and 651 vs 150 after second dose). We will continue to
investigate whether RT-qPCR results can be used to predict
protective efficacy.
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A number of studies of PfSPZ vaccines have shown that pro-
tected vaccinees had significantly higher antibodies to PfSPZ as
measured by PfCSP ELISA, PfSPZ immunofluorescence assay,
and/or inhibition of sporozoite invasion of hepatocytes10,11. In
our previous study of PfSPZ-CVac, the nine highest dose subjects
had the highest levels of antibodies to PfCSP, but all were pro-
tected, so we could not try to correlate protection with antibody
level. In the intermediate dose group 6/9 were protected, and the
difference in PfCSP antibody levels between protected and
infected subjects was not significant12. In this study the 10 pro-
tected vaccinees had significantly higher levels of antibodies to
PfCSP 2 weeks after the last immunization, and prior to CHMI,
than did the three infected vaccinees. This indicates that anti-
PfCSP antibodies either play a role in protection and/or are a
biomarker for other protective immune responses. In animal
studies protection by sporozoite vaccines is dependent on cellular
immune responses, especially CD8 T cells24,25. Thus, the anti-
PfCSP antibody levels can serve as a correlate of protection, even
though we cannot elucidate the mechanistic function in this work.
Nevertheless, PfCSP-specific antibodies are highly functional in
inhibiting sporozoite invasion into the liver and were recently
shown to neutralize sporozoites in the liver26,27.
In our previous work, using a whole proteome microarray, 22
antigens were identified by qualitative analysis as specifically
immunogenic (recognized by 5/9 subjects) after immunization
with 5.12 × 104 PfSPZ of PfSPZ-CVac12. Of these 22 antigens, 7
were on the microarray used in this study, including PfCSP,
PfMSP4, PfLSA1, PfGLURP, PfLISP2, and two unknown function
antigens. Our microarray data confirm the immunogenicity of
PfCSP, PfLSA1, and PfLISP2 but we did not identify elevated
antibodies against PfMSP4, PfGLURP, or the two unknown
function antigens. In addition, we confirmed the immunogenicity
of PfMSP2, which has been described before12,18,20. We also
identified several novel or less considered markers of vaccination.
These include PfMSA180, a protein with unknown function
(PF3D7_01083Na00) and the sporozoite surface protein,
PfSIAP2. In the microarray studies, only PfMSP2 was consistently
recognized by sera from protected vs infected subjects (Fig. 7d).
The expression of the antigen PfMSP2 has been confirmed by
immunofluorescence in day 5 Pf liver stage28. This result shows
that vaccine-induced immunity to the late liver stage is of
importance for the protection. The majority of identified immune
markers, especially LSA1 (ref. 29) and MSP2 (ref. 30), but also
SIAP2 (ref. 31) and most recently MSA180 (ref. 31), a merozoite
surface protein with assumed function during erythrocyte inva-
sion, have been suggested as promising targets for peptide-based
vaccines32.
Despite the promising, high level and cross-strain protection,
our study has limitations. The number of participants in this early
phase of clinical development was low. Thus, possible individual
differences could lead to overrepresentation of chance effects.
Furthermore, the longevity of protection beyond 12 weeks
induced by this condensed PfSPZ-CVac regimen needs to be
followed-up. The long-term protection against heterologous
CHMI is part of the study protocol and will be further investi-
gated. However, in the CPS model, durable immunity for
28 months against homologous CHMI was achieved14.
A 4-week immunization regimen with PfSPZ-CVac, in which
the PfSPZ and CQ were administered on the three same days
(Days 1, 6, and 29), was a practical and effective immunization
strategy that reached more than 75% cross-strain protection in
CHMI 12 weeks after immunization. This work is an important
step in the clinical development of PfSPZ-CVac for protection
against malaria and a milestone towards regulatory approval.
Further optimization of the study regimen will include the
replacement of oral CQ as the chemoprophylactic drug. To
increase tolerability of vaccination and to ensure the adminis-
tration of the drug, we aim to replace oral CQ by intramuscular
pyronaridine.
We believe that PfSPZ-CVac will be an excellent vaccine for
travelers to Africa, as usually more than 90% of travelers are
voyaging for less than 12 weeks, and a vaccination regimen as
proposed here can be well-included into the travel preparation.
However, our major goal is to conduct studies to assess PfSPZ-
CVac in 2–12-year-old African children, the demographic group
that suffers the greatest morbidity and mortality from malaria,
and is responsible for most of the transmission of malaria33.
We believe that PfSPZ-CVac will be able to meet the strategic
goals of the WHO Preferred Product Characteristics for Malaria
Vaccines34.
Methods
Design and participants. This single-center, double-blinded, randomized trial was
conducted at the Institute of Tropical Medicine, University of Tübingen, Tübingen,
Germany, from April 2019. Screening was started on 2 May 2019 and first vac-
cination was done on 15 May 2019. The last volunteer was vaccinated on 23 May
2019. Planned trial close out was November 2020, but this had to be postponed due
to the COVID-19 pandemic. Therefore, it was decided to report the data of this
interim analysis. The first CHMI was performed in September 2019 with a follow-
up until November 2019. This interim analysis on the vaccine safety, efficacy, and
immunogenicity was predetermined in advance in the study protocol, and the
safety monitoring committee reviewed the reports on safety and tolerability data.
The trial was approved by the Paul Ehrlich Institute and the Clinical Ethics
Committee at the University Hospital of Tübingen (UKT). The study design and
conduct complied with all relevant regulations regarding trials with human study
participants and was conducted in accordance with the criteria set by the
Declaration of Helsinki. The study was performed in accordance with Good
Clinical Practice/International Conference on Harmonisation guidelines. The trial
is registered in the European Union Clinical Trials Register (EudraCT-Nr: 2018-
004523-36).
Healthy, malaria-naive volunteers aged 18–45 were recruited in Tübingen and
surrounding areas. All participants provided written informed consent at the
screening visit. Female volunteers were required to practice continuous effective
birth control during the study period. For safety reasons, volunteers were required
to be reachable 24/7 by mobile phone. Prior to enrollment, participants had to pass
a questionnaire assessing the understanding of risks and obligations of the trial.
Main exclusion criteria were history of malaria or previous participation in a
malaria vaccine trial and any relevant medical history. The full list of eligibility
criteria is listed in the protocol which is available in the supplementary material.
Procedures. Participants were randomly allocated to immunization with either
1.1 × 105 PfSPZ of PfSPZ Challenge (PfNF54) or normal saline as placebo on the
day of first vaccination. All vaccinations were administered by DVI in 0.5 ml on
Days 1, 6, and 29.
All volunteers received 10 mg/kg CQ base orally (up to a maximum dose of
620 mg CQ base) within 2 h prior to each immunization (Resochin, Bayer Schering
Pharma). PfSPZ Challenge (PfNF54) for immunization consisted of aseptic,
purified, cryopreserved, infectious PfSPZ, strain PfNF54, produced by Sanaria Inc.
(Rockville, USA). PfSPZ were stored and transported in liquid nitrogen vapor
phase and thawed and diluted at the Institute of Tropical Medicine, Tübingen
within 20 min before DVI.
Twelve weeks after the last dose of immunization with PfSPZ or placebo, all
volunteers underwent CHMI by DVI of 3.2 × 103 PfSPZ Challenge22, using the
heterologous Pf strain 7G8 to assess VE. Pf7G8 is derived from a Brazilian isolate35,
is antigenically highly divergent from PfNF54 the West African vaccine strain21,
and in prior challenge studies has been harder to protect against than for CHMI
using homologous PfNF54 (ref. 10), thereby increasing the stringency of the CHMI.
Thick blood smear (TBS) and RT-qPCR were performed daily from Day 6 to 21
and on all later follow-up visits (Day 28 and 56) after CHMI as described earlier12.
Subjects were treated regardless of symptoms in case of TBS positivity or three
positive PCR results, at least 12 h apart and at least one of them above 100
parasites/ml. First-line treatment was 1000 mg atovaquone and 400 mg proguanil
once daily for three consecutive days.
Randomization and masking. Randomization was performed on the day of first
immunization prior to injection by a third party outside the study team and
sponsor. The randomization list was generated using a random number generator
(Mersenne-Twister implemented in R; www.r-project.org) and given to a dedicated
member of the formulation team who did not have a further role in the trial. The
allocation ratio for PfSPZ Challenge to placebo was 2:1. All syringes used were
identical and labeled with the volunteer identification code. PfSPZ Challenge
(PfNF54) and placebo were both clear fluids and not distinguishable by appearance
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or consistency. Clinical team, funder, and volunteers remained blinded until
database lock. First unblinding was done following an interim database lock after
Day 56 of CHMI to allow assessment of VE by an independent statistician.
Outcomes. The aim of the trial was to assess safety, tolerability, and efficacy of a
condensed immunization regimen with three doses of PfSPZ Challenge and CQ.
The primary VE endpoint was the proportion of protected volunteers. Protection
was defined as the absence of parasitemia in the peripheral blood for 28 days after
CHMI. According to the study protocol, parasitemia was defined as at least one
RT-qPCR result above 100 parasites/ml among three positive results, at least 12 h
apart or as a positive TBS.
The primary safety endpoint was the occurrence of related grade 3 and 4 AEs
events following the first CQ administration until the end of the trial. Related AEs
were recorded and reported using the terminology defined in the Medical
Dictionary for Regulatory Activities (MedDRA).
Further exploratory endpoints were time to parasitemia (defined as the time to
the first positive RT-qPCR result among three positive results at least 12 h apart,
with at least one of them being above 100 parasites/ml, or the time to a positive
TBS) and the characterization of immune responses including the identification of
parasitological and immunological correlates of protection against CHMI.
Immunological assays. IgG and IgM antibodies to the PfCSP were assessed by
titration ELISA, and in addition by quantitative ELISA, as described12,36. Antibody
reactivity against Pf antigens was assessed by protein microarray (array design in
supplementary Table 1). The array comprises 262 Pf protein fragments repre-
senting 228 unique proteins down-selected from previous larger microarray
screens19,20 and performed as described37. A detailed description of the immu-
nological assays is available in the supplement.
Statistical analysis and sample size. To detect infection rates of 25% or less in
the vaccination and 85% in the placebo groups (allocated in a 2:1 ratio) with a
power of 80% and a two-tailed alpha of 5%, 14 PfSPZ-CVac immunized, and 7
placebo-treated volunteers were required. Sample size was calculated in R using the
nBinomial function provided in the gsDesign package v3.2.
Safety and tolerability data are presented as descriptive analyses. VE was
calculated as 1−relative risk of reaching the parasitemia endpoint for vaccinated
participants compared to unvaccinated participants. Proportions between
immunized and placebo-treated volunteers were compared with an unconditional
exact test (Boschloo’s test) using R (exact2x2 package v1.6.5). The level of
significance was set at a two-tailed type 1 error alpha <5%.
Participants, investigators, and diagnostic team remain blinded until
completion of all CHMI procedures and data collection.
All statistical analyses were performed using R, version 4.0.4, and GraphPad
Prism 9.0.2.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Individual participant data that underlie the results reported in this publication are
available from the clinical trial sponsor on the basis of a data sharing agreement on
reasonable request. The data are not publicly available due to them containing
information that could compromise research participant privacy and consent. The study
protocol is available in the supplementary material. Correspondence should be submitted
to R.F. (rolf.fendel@uni-tuebingen.de).
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